Last updated on February 2018

Evaluation of the Safety Tolerability and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease


Brief description of study

This is a Phase 1b, open-label, dose-escalation, signal-finding, single center study. The study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of MDGN-002 in adults with moderate to severe, active Crohn's disease who have previously failed anti-tumor necrosis factor alpha (anti-TNF) treatment.

Clinical Study Identifier: NCT03169894

Contact Investigators or Research Sites near you

Start Over

Caitlin Walsh

The Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia
Philadelphia, PA United States
  Connect »